SBL03
Geographic Atrophy in Dry Age-Related Macular Degeneration (AMD)
Pre-clinicalActive
Key Facts
Indication
Geographic Atrophy in Dry Age-Related Macular Degeneration (AMD)
Phase
Pre-clinical
Status
Active
Company
About SeaBeLife Biotech
SeaBeLife Biotech is pioneering a novel therapeutic approach by developing dual inhibitors of regulated necrosis pathways (necroptosis and ferroptosis), a mechanism implicated in a wide range of severe organ diseases. Its most advanced program, SBL03, is a topical ophthalmic gel for geographic atrophy (GA) in dry AMD, which has shown promising preclinical efficacy and secured an Orphan Drug Designation from the EMA. The company is privately held, pre-revenue, and operates with a capital-efficient model through strategic partnerships, such as its joint development agreement with Unither Pharmaceuticals, to advance its pipeline from preclinical to clinical stages.
View full company profile